Misra 2011.

Methods	Randomised, open‐label study
Participants	Adult patients, mean age for Lorazepam group 38.90 and Levetiracetam group 39.16 years Consecutive patients with either convulsive SE or subtle convulsive SE were recruited
Interventions	Levetiracetam: 20 mg/kg IV over 15 min Lorazepam: 0.1 mg/kg IV over 2‐4 min
Outcomes	Control of seizure, adverse events such as hypotension, respiratory failure, pneumonia, UTI, ventilatory need, days of ventilation, hepatitis, rash, agitation, thrombocytopenia and deaths
Notes	Study conducted in India
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number tables were used
Allocation concealment (selection bias)	High risk	No concealment
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label study
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Even though not blinded, outcomes such as seizure activity determination and occurrence of adverse events are unlikely to be subject to bias in detection